Independent Franchise Partners LLP Boosts Holdings in Solventum Corporation $SOLV

Independent Franchise Partners LLP raised its stake in shares of Solventum Corporation (NYSE:SOLV) by 19.0% during the 4th quarter, according to the company in its most recent filing with the SEC. The firm owned 15,355,691 shares of the company’s stock after purchasing an additional 2,456,451 shares during the quarter. Solventum accounts for about 7.7% of Independent Franchise Partners LLP’s investment portfolio, making the stock its biggest position. Independent Franchise Partners LLP owned about 8.85% of Solventum worth $1,216,785,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds also recently made changes to their positions in the stock. Assetmark Inc. increased its holdings in shares of Solventum by 21.4% during the 4th quarter. Assetmark Inc. now owns 725 shares of the company’s stock worth $57,000 after purchasing an additional 128 shares during the period. Hilltop National Bank increased its holdings in shares of Solventum by 71.3% during the 4th quarter. Hilltop National Bank now owns 310 shares of the company’s stock worth $25,000 after purchasing an additional 129 shares during the period. Allworth Financial LP increased its holdings in shares of Solventum by 2.8% during the 3rd quarter. Allworth Financial LP now owns 4,788 shares of the company’s stock worth $350,000 after purchasing an additional 129 shares during the period. CIBC Private Wealth Group LLC increased its holdings in shares of Solventum by 0.5% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 24,710 shares of the company’s stock worth $1,804,000 after purchasing an additional 134 shares during the period. Finally, BOKF NA increased its holdings in shares of Solventum by 6.9% during the 3rd quarter. BOKF NA now owns 2,193 shares of the company’s stock worth $160,000 after purchasing an additional 141 shares during the period.

Wall Street Analyst Weigh In

A number of analysts recently weighed in on SOLV shares. Piper Sandler lowered their target price on shares of Solventum from $98.00 to $92.00 and set an “overweight” rating on the stock in a research note on Friday, April 17th. Wall Street Zen cut shares of Solventum from a “buy” rating to a “hold” rating in a research note on Sunday, March 8th. BTIG Research reissued a “buy” rating and issued a $89.00 target price on shares of Solventum in a research note on Wednesday, May 6th. Wells Fargo & Company lowered their target price on shares of Solventum from $83.00 to $70.00 and set an “equal weight” rating on the stock in a research note on Wednesday, May 6th. Finally, Stifel Nicolaus lowered their target price on shares of Solventum from $105.00 to $90.00 and set a “buy” rating on the stock in a research note on Wednesday, May 6th. Eight investment analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Solventum presently has a consensus rating of “Moderate Buy” and an average target price of $84.25.

Solventum Price Performance

Shares of Solventum stock opened at $74.48 on Thursday. The company has a current ratio of 1.07, a quick ratio of 0.75 and a debt-to-equity ratio of 0.96. The stock has a market capitalization of $12.90 billion, a price-to-earnings ratio of 9.13, a P/E/G ratio of 1.18 and a beta of 0.69. Solventum Corporation has a 1-year low of $62.38 and a 1-year high of $88.20. The firm’s 50-day moving average price is $73.25 and its two-hundred day moving average price is $75.00.

Solventum (NYSE:SOLV) last announced its earnings results on Tuesday, May 5th. The company reported $1.48 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.35 by $0.13. Solventum had a net margin of 17.33% and a return on equity of 23.51%. The company had revenue of $2.01 billion for the quarter, compared to analyst estimates of $1.97 billion. During the same period in the prior year, the business earned $1.34 earnings per share. Solventum’s quarterly revenue was down 3.0% on a year-over-year basis. Solventum has set its FY 2026 guidance at 6.600-6.600 EPS. On average, equities analysts predict that Solventum Corporation will post 6.58 earnings per share for the current fiscal year.

Solventum Profile

Solventum Corporation, a healthcare company, engages in the developing, manufacturing, and commercializing a portfolio of solutions to address critical customer and patient needs. It operates through four segments: Medsurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The Medsurg segment is a provider of solutions including advanced wound care, I.V. site management, sterilization assurance, temperature management, surgical supplies, stethoscopes, and medical electrodes.